ArticleExperimental hematology & oncology2012
CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.
Article in Experimental hematology & oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07422337 (Blinatumomab's Outcome On Serologic Titers and Efficacy of Revaccination), which is not on this map. Cited by 315 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Blinatumomab's Outcome On Serologic Titers and Efficacy of Revaccination
Who cites it
315 citing papers in PubMed, 1 synthesis or guideline pooled it, 552 citations in OpenAlex.
- The Immunomodulatory Effect of Vitamin B12 in Pernicious Anemia: A Systematic Review.Oxidative medicine and cellular longevity · 2025Pooled it
- Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma.The AAPS journal · 2021Trial
- CAR-T-centered sequential therapy: current status, challenges, and future clinical perspectives.Journal of hematology & oncology · 2026Review
- Real-world safety and efficacy of blinatumomab for EBV viremia and EBV-related PTLD after allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation · 2026Article
- RHOA Deletion Downregulates CD19 and Promotes Dysfunctional Immune Microenvironments in CAR-T Resistant Large B-cell Lymphomas.Blood cancer discovery · 2026Article
- Differential expression of lymphocyte markers by neighborhood opportunity among US adults: Insights from the Midlife in the United States study.Psychoneuroendocrinology · 2026Article
- Scalable, generalizable and uncertainty-aware integration of spatial multiomics across diverse modalities and platforms with SCIGMA.Nature genetics · 2026Article
- CAR T cell therapy beyond cancer: current status, challenges and future prospects.Signal transduction and targeted therapy · 2026Review
- Impact of CD38 Deficiency on B Cell Development in CD19-Deficient Mice.Scandinavian journal of immunology · 2026Article
- Effectiveness and Safety of Inebilizumab for IgG4-Related Disease in a Real-World Clinical Setting in Japan: Protocol for a Long-Term Prospective Observational Study (4SigHT Study).Rheumatology and therapy · 2026Article
- Development of tandem canine CAR T cells to enable comparative studies of aggressive B-cell lymphoma.Molecular cancer therapeutics · 2026Article
- Christensenella minuta DSM 22607 and Food Restriction Manage Age-Related Disorders In Vivo.Probiotics and antimicrobial proteins · 2026Article
- DNA methylation-based immune cell profiling in mouse blood using MouseRS-CMD.Genome biology · 2026Article
- Biomimetic bone calcium phosphate-based scaffolds fabricated via ceramic vat photopolymerization: Effect of porosity, sintering temperature, mineralogical phases and trace elements on the osteogenic potential.Materials today. Bio · 2026Article
- Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies.British journal of clinical pharmacology · 2026Article
- Regulatory challenges of personalized medicine in the real world: are the right patients being treated with CD19-targeting CAR T-cells?EMBO molecular medicine · 2026Review
- scHG: A supercell framework with high-order graph learning enables scalable multi-omics analysis.PLoS computational biology · 2026Article
- Antibody-Drug Conjugates (ADCs): A Review of Structural Design, Technological Evolution, and Future Perspectives.Molecules (Basel, Switzerland) · 2026Review
- Oral Islatravir in Macaques Decreases Lymphocytes and Monocytes and Is Associated with Immune Alterations.Pharmaceutics · 2026Article
- Molecular Signatures of Blood Biomarkers in Depression: Gene Expression Analysis ofDiagnostics (Basel, Switzerland) · 2026Article
255 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human CD19 antigen is a 95 kd transmembrane glycoprotein belonging to the immunoglobulin superfamily. CD19 is classified as a type I transmembrane protein, with a single transmembrane domain, a cytoplasmic C-terminus, and extracellular N-terminus. CD19 is a biomarker for normal and neoplastic B cells, as well as follicular dendritic cells. CD19 is critically involved in establishing intrinsic B cell signaling thresholds through modulating both B cell receptor-dependent and independent signaling. CD19 functions as the dominant signaling component of a multimolecular complex on the surface of mature B cells, alongside complement receptor CD21, and the tetraspanin membrane protein CD81 (TAPA-1), as well as CD225. Through study of CD19 transgenic and knockout mouse models, it becomes clear that CD19 plays a critical role in maintaining the balance between humoral, antigen-induced response and tolerance induction. This review also summarized latest clinical development of CD19 antibodies, anti-B4-bR (an immunotoxin conjugate), blinatumomab (BiTE), and SAR3419 (huB4-DM4), a novel antibody-drug conjugate.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.